France Leads Europe In Reimbursing Truvada For HIV Prophylaxis
This article was originally published in Scrip
Gilead Sciences' HIV drug Truvada is now being reimbursed in France for pre-exposure prophylaxis (PrEP) under a "temporary use recommendation" (RTU) that came into effect on Jan. 4. This is understood to be the first European country where Truvada can be officially prescribed and reimbursed for PrEP, an indication for which it has not yet received an EU marketing authorization.
You may also be interested in...
The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.